The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Dr. Heather Parsons of Dana-Farber Cancer Institute explains how a liquid biopsy could help patients with breast cancer and their care teams learn vital information.